Before profiling Raleigh-based Adamas Nano, a definition is in order for its core business – nanodiamonds.

What are nanodiamonds?

Says Wikipedia: “[They] are diamonds with a size below 1 micrometre. They can be produced by impact events such as an explosion or meteoritic impacts. A single imperfection can give a nanodiamondan isolated color center, which lets it function as single, trapped atom.”

There are multiple uses for nanodiamonds, from anti-counterfeiting to life science R&D. Adamas will be explaining its business as a presenter at the CED Tech Venture Conference.

And there is need for them, as proven by the National Institutes of Health in a grant award as noted by Adamas: “After successful completion of a Phase I SBIR grant demonstrating high fluorescent efficiency in 80nm nanodiamond particles, Adámas was awarded a contract from the National Institute of Health to further refine the technology and produce nanodiamonds functionalized with proteins and antibodies.”

Here’s the Q&A of the company, the 21st in a series of profiles being published by WRAL TechWire in partnership with the CED.:

  • What is the focus of your business?

Adámas is dedicated to development and production of nanodiamond particles with unique properties. Adámas also focuses on their implementation in related applications and development of new technologies, such as the use of fluorescent nanodiamonds in Life Science medical and research applications, as well as anti-counterfeiting.

Furthermore, we have developed a nanodiamond based lubricant which significantly increases fuel efficiency.

  • What is the top pain point/business application you are seeking to address?

The lack of non-toxic, photostable fluorescent particles for life science research and medical applications.

  • What makes it unique?

Nanodiamonds do not degrade or lose their fluorescent qualities over time, and are non-toxic. They can also be used as carriers for drug and biomolecule delivery, and they can be easily conjugated with antibodies.

This makes them more versatile than any other products currently on the market.

  • Why should investors be interested in your firm?

We offer a unique product platform for a variety of medical and research problems in life science. Furthermore, we are currently in Phase II of an SBIR contract from the NIH for the development of fluorescent nanodiamonds.

Business facts:

  • Website – http://www.adamasnano.com
  • Email address for inquiries – oshenderova@adamasnano.com
  • Physical address – 8100 Brownleigh Drive, Raleigh NC    
  • CEO – Olga Shenderova